Evaluation of lymph nodes in women undergoing neoadjuvant chemotherapy in the treatment of breast cancer

Autores

  • Rosana Zabulon Feijó Belluco Universidade do Distrito Federal, Escola Superior de Ciências da Saúde – Brasília (DF), Brazil.
  • Letícia Sousa Amâncio da Costa Fundação de Ensino e Pesquisa em Ciências da Saúde, Hospital Regional da Asa Norte – Brasília (DF), Brazil.
  • Camila Taveira de Castro Universidade Católica de Brasília – Brasília (DF), Brazil.
  • Ricardo Sousa Amancio da Costa Centro Universitário do Planalto Central – Brasília (DF), Brazil.
  • Camila Gomes de Souza Fundação de Ensino e Pesquisa em Ciências da Saúde, Hospital Regional da Asa Norte – Brasília (DF), Brazil.
  • Pâmela Micaella Araujo Pinto Fundação de Ensino e Pesquisa em Ciências da Saúde, Hospital Regional da Asa Norte – Brasília (DF), Brazil.
  • Gustavo de Oliveira Mota Maciel Fundação de Ensino e Pesquisa em Ciências da Saúde, Hospital Regional da Asa Norte – Brasília (DF), Brazil.
  • Júllia Eduarda Feijó Belluco Centro Universitário Euro Americano – Brasília (DF), Brazil.

DOI:

https://doi.org/10.29289/259453942025V35S1096

Palavras-chave:

breast cancer, neoadjuvant chemotherapy, sentinel lymph node, lymphadenectomy, athologic complete response

Resumo

Objective: To evaluate the impact of neoadjuvant chemotherapy on the surgical management of axillary lymph nodes,
focusing on the feasibility of more conservative interventions. Methods: This observational, analytical, and cross-sectional
study analyzed the medical records of 172 women diagnosed with breast cancer at the Regional Hospital of Asa Norte,
between June 2021 and August 2024. Among them, 21 met the inclusion criteria. The study was submitted and approved
by the ethics committee (CAAE: 85735824600005553; Opinion: 7429411). Results: The mean age of the participants was
52.8 years. Breast involvement was evenly distributed between the right and left sides (47.62% each), while 4.76% had bilateral involvement. The most prevalent molecular subtype was luminal B (33.33%), followed by human epidermal growth
factor receptor-type 2-positive (HER2+) (28.57%), triple negative (19.04%), and luminal A (14.28%). The average tumor size
was 3.7 cm, being the most common (57.14%), with tumors measuring from 2.1 to 3.0 cm. Axillary staging showed 52.38%
with negative nodes and 47.62% with positive nodes. Partial response to chemotherapy was the most frequent outcome
(42.86%), while 23.81% achieved pathological complete response and 33.33% showed no response. Surgically, 66.67% underwent mastectomy and 33.33% underwent conservative surgery. Sentinel lymph node biopsy was the predominant axillary
approach (57.14%), while 42.86% required lymphadenectomy. Clear margins were observed in 90.48% of cases. The mean
number of evaluated lymph nodes was 10.33, with an average of 3.28 positive nodes. Conclusion: Neoadjuvant chemotherapy contributed to reducing lymph node involvement, enabling more conservative surgical techniques, such as sentinel lymph node biopsy, with lower morbidity. Therefore, personalized treatment, considering tumor profile and therapeutic response, is essential to improve clinical outcomes and patients’ quality of life.

Downloads

Não há dados estatísticos.

Downloads

Publicado

2026-02-24

Como Citar

Belluco, R. Z. F., Costa, L. S. A. da, Castro, C. T. de, Costa, R. S. A. da, Souza, C. G. de, Pinto, P. M. A., … Belluco, J. E. F. (2026). Evaluation of lymph nodes in women undergoing neoadjuvant chemotherapy in the treatment of breast cancer. Mastology, 35(suppl.1). https://doi.org/10.29289/259453942025V35S1096

Edição

Seção

E-poster